Senate Minority Leader Charles Schumer, D-N.Y., called for an ethics probe of President-elect Donald Trump's HHS secretary nominee Rep. Tom Price, MD, R.-Ga., earlier this week. In a letter to HHS dated Jan. 11, Rep. Price sought to clarify his investments and plans to eliminate any conflicts of interest.
Rep. Price has investments in several companies; some he plans to divest while others he would retain limited partnership interest.
Here are the 43 companies Rep. Price that he'll divest his interest in if confirmed as HHS secretary:
1. Aetna Inc.
2. Alphabet Inc.
3. Amazon.com Inc.
4. American Tower REIT
5. Amgen Inc.
6. Apple Inc.
7. Arch Capital Group
8. Arris International
9. Athenahealth Inc.
10. Biogen Inc.
11. Bristol Myers Squibb Co.
12. Calpine Corp.
13. CBS Corp.
14. Cognizant Tech Solutions
15. Crown Castle Intl Corp.
16. CVS Health Corp.
17. Danaher Corp.
18. Delta Airlines, Inc.
19. Eli Lilly & Co.
20. Facebook Inc.
21. Hewlett Packard, Inc.
22. Honeywell Corp.
23. Innate Immunotherapeutics
24. Jazz Pharmaceuticals
25. Kansas City Southern
26. L Brands Inc.
27. Lyondellbasell Industries
28. McKesson Corp.
29. Nextera Energy Inc.
30. Northrop Grumman Corp.
31. PG&E Corp.
32. Pfizer Inc.
33. Qihoo 360 Technology Co.
34. Sempra Energy
35. Starbucks Corp.
36. Thermo Fisher Scientific, Inc.
37. Union Pacific Corp.
38. United Technologies Corp.
39. Verizon Communications Inc.
40. Whitewave Foods Corp.
41. Xerox Corp.
42. XL Group
43. Zimmer Biomet Holdings Inc.
Here are the two companies — both of which rent to healthcare-related tenants — that he would retain a limited partnership in:
1. Diagnostic Ventures
2. RMC3
Rep. Price also plans to retain interest in the physician practice Chattahoochee Associates, but would resign his post.